Pipeline

Aduro’s extensive pipeline of diverse product candidates builds from three proprietary technology platforms (STING Pathway Activators, B-select monoclonal antibodies and Live, Attenuated Double Deleted Listeria (LADD®) to create immunotherapies targeting a variety of cancers, as well as infectious and autoimmune diseases.

STING Pathway Programs

ADU-S100

Multiple tumors
 
     

ADU-S100

Multiple tumors
antiPD-1
     

Adjuvant

Infectious Disease
 
     

STING-Blok

Autoimmune Disease
 
     
Indication
Combination

B-select Programs

Anti-APRIL

Multiple Myeloma
 
     

Anti-CD27 agonist

Oncology
 
     

Anti-CTLA4

Oncology
 
     

Bispecific Ab

Oncology
 
     
Indication
Combination

LADD Programs

pLADD

MSS Colorectal
 
     

ADU-741

Prostate
 
     

ADU-214

Lung
 
     
Indication
Combination